Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Repotrectinib - Bristol-Myers Squibb

Next Previous
Drug Profile

Repotrectinib - Bristol-Myers Squibb

Alternative Names: AUGTYRO; BMS-986472; Ropotrectinib; TPX 0005; ZL-2308

Latest Information Update: 27 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TP Therapeutics
  • Developer Bristol-Myers Squibb; Turning Point Therapeutics; ZAI Lab
  • Class Antineoplastics; Aza compounds; Fluorobenzenes; Ketones; Macrocyclic compounds; Pyrazoles; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion protein tyrosine kinase inhibitors; Janus kinase 2 inhibitors; ROS1 protein inhibitors; Src-family kinase inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Solid tumours
  • Phase II Adenocarcinoma
  • Phase I/II CNS cancer; Lymphoma
  • Preclinical Multiple myeloma

Most Recent Events

  • 27 May 2026 Launched for Solid tumours (Metastatic disease, Late-stage disease, In adults) in China (PO)
  • 19 Mar 2026 Bristol-Myers Squibb completes a phase I PK trial (In volunteers) in USA (NCT07223671)
  • 06 Jan 2026 Registered for Solid tumours (Late-stage disease, Metastatic disease, In adults) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top